A scientist at Gilead Sciences analyzes affected person antibody ranges on the Gilead laboratory in Foster City, California.
David Paul Morris | Bloomberg | Getty Images
Gilead Sciences stated on Monday it had determined to stop a late-stage trial of its intravenous treatment, Veklury, in high-risk non-hospitalized sufferers with Covid-19.
The firm stated it now not believes that growing a multiple-day injection that requires administration in a healthcare setting addresses an unmet want for non-hospitalized sufferers.
The determination to stop the study is just not due to efficacy or security issues, Gilead stated.